Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Screening
Sensitivity of AMAS test insufficient to allow for population screening
December 8th, 2005
The sensitivity of the anti-malignin antibody serum (AMAS) test is insufficient to allow it use for population screening. "The AMAS test (Oncolab, Boston, MA) has been reported as 97% sensitive and 95% specific for malignancies. To objectively assess accuracy of this test for discrimination of breast cancer," S. M. Harman and colleagues "studied a series of women undergoing core breast biopsy. Seventy-one core-needle breast biopsies were classified as malignant, suspicious, or benign by two independent pathologists blinded to AMAS results." The researchers explained, "Corresponding sera were read as AMAS positive, negative, or borderline by criteria...
Source: Women's Health Weekly (2005-12-08)
|
